{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-022970","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2023-03-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.340393+00:00","generated_at":"2026-06-17T14:47:28.906982+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Silo Pharma files provisional patent for ketamine pain management (SP-26) targeting fibromyalgia.","bullets":["Provisional patent titled 'Methods and Compositions for Pain Management' covers chronic pain including fibromyalgia.","Fibromyalgia affects approximately 2% of the U.S. population; initially targeted indication for company drug SP-26.","Company is working towards submitting an IND package to FDA under 505(b)(2) regulatory pathway for SP-26.","CEO Eric Weisblum states patent supports multi-pronged strategy to advance SP-26 into the clinic.","Silo Pharma holds over six issued and provisional patents in rare disease space."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-022970","json":"https://secwatch.observer/filing/0001213900-23-022970.json","markdown":"https://secwatch.observer/filing/0001213900-23-022970.md","text":"https://secwatch.observer/filing/0001213900-23-022970.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023022970/0001213900-23-022970-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390023022970/ea175769-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T14:47:28.906982+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}